TY - JOUR
T1 - Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
AU - Hotta, Katsuyuki
AU - Fujimoto, Nobukazu
N1 - Funding Information:
Contributors KH and NF carried out the search and assessement for relevant studies. KH drafted the manuscript. Both authors read and approved the final manuscript. Funding This study was supported by grants-in-aid from the Ministry of Health, Labor and Welfare, Japan. Competing interests KH has honoraria from AstraZeneca, Ono Pharmaceuticals, BMS, MSD, Eli Lilly Japan, Nihon Kayaku, Taiho Pharmaceuticals and Chugai Pharmaceuticals, as well as unrelated research funding from AstraZeneca, BMS, and Eli Lilly Japan. NF has received consultancy fees from Boehringer Ingelheim, Ono, Bristol-Myers Squibb, Kyorin, and Kissei, and honoraria or research funding from Ono, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly Japan, and MSD
Publisher Copyright:
© 2020 Author(s).
PY - 2020/2/24
Y1 - 2020/2/24
N2 - Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.
AB - Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.
UR - http://www.scopus.com/inward/record.url?scp=85080878163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080878163&partnerID=8YFLogxK
U2 - 10.1136/jitc-2019-000461
DO - 10.1136/jitc-2019-000461
M3 - Review article
C2 - 32098830
AN - SCOPUS:85080878163
SN - 2051-1426
VL - 8
JO - Journal for immunotherapy of cancer
JF - Journal for immunotherapy of cancer
IS - 1
M1 - e000461
ER -